These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23846924)

  • 21. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001.
    Hejna M; Raderer M; Zacherl J; Ba-Ssalamah A; Püspök A; Schmidinger M; Pluschnig U; Brodowicz T; Zielinski CC
    Anticancer Drugs; 2008 Jun; 19(5):535-9. PubMed ID: 18418220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.
    Vyzula R; Kocáková I; Demlová R; Kiss I; Dusek L; Jarkovský J
    Neoplasma; 2006; 53(2):119-27. PubMed ID: 16575467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):105-11. PubMed ID: 21382702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer.
    Syrigos KN; Michalaki B; Alevyzaki F; Machairas A; Mandrekas D; Kindilidis K; Karatzas G
    Anticancer Res; 2002; 22(6B):3583-8. PubMed ID: 12552960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New option for the initial management of metastatic pancreatic cancer?
    Abbruzzese JL; Hess KR
    J Clin Oncol; 2014 Aug; 32(23):2405-7. PubMed ID: 24982449
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    Lemstrova R; Melichar B; Mohelnikova-Duchonova B
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas.
    Miwa H; Sugimori K; Ishii T; Funaoka A; Tsuchiya H; Suzuki Y; Sugimori M; Nishimura M; Tozuka Y; Komiyama S; Sato T; Kaneko T; Numata K; Maeda S
    Intern Med; 2021 Aug; 60(16):2607-2612. PubMed ID: 33642489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic cancer: standing on the shoulders of mice, making an iMPACT on pancreatic cancer.
    Villanueva MT
    Nat Rev Clin Oncol; 2013 Dec; 10(12):665. PubMed ID: 24189469
    [No Abstract]   [Full Text] [Related]  

  • 29. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
    Neesse A; Michl P; Tuveson DA; Ellenrieder V
    Z Gastroenterol; 2014 Apr; 52(4):360-6. PubMed ID: 24687799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second line treatment options for pancreatic cancer.
    Passero FC; Saif MW
    Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action.
    Al-Batran SE; Geissler M; Seufferlein T; Oettle H
    Oncol Res Treat; 2014; 37(3):128-34. PubMed ID: 24685917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA-associated pancreatic cancer: the evolving management.
    Leung K; Saif MW
    JOP; 2013 Mar; 14(2):149-51. PubMed ID: 23474559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nab-paclitaxel in patients with metastatic melanoma.
    Leon-Ferre RA; Markovic SN
    Expert Rev Anticancer Ther; 2015; 15(12):1371-7. PubMed ID: 26536477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
    Gupta A; Duque M; Saif MW
    JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Target therapies in pancreatic carcinoma.
    Silvestris N; Gnoni A; Brunetti AE; Vincenti L; Santini D; Tonini G; Merchionne F; Maiello E; Lorusso V; Nardulli P; Azzariti A; Reni M
    Curr Med Chem; 2014; 21(8):948-65. PubMed ID: 23992319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promising novel cytotoxic agents and combinations in metastatic prostate cancer.
    Bradley DA; Hussain M
    Cancer J; 2008; 14(1):15-9. PubMed ID: 18303478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promising new therapies in advanced pancreatic adenocarcinomas.
    Kundranda M; Kachaamy T
    Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Currently available first-line drug therapies for treating pancreatic cancer.
    Olson JL; Bold RJ
    Expert Opin Pharmacother; 2018 Dec; 19(17):1927-1940. PubMed ID: 30325679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel.
    Bianconi D; Heller G; Spies D; Herac M; Gleiss A; Liebmann-Reindl S; Unseld M; Kieler M; Scheithauer W; Streubel B; Zielinski CC; Prager GW
    Sci Rep; 2017 Jul; 7(1):4851. PubMed ID: 28687745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
    Weinberg BA; Yabar CS; Brody JR; Pishvaian MJ
    Oncology (Williston Park); 2015 Nov; 29(11):809-20, 886. PubMed ID: 26573060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.